Congenital heart disease (CHD) is the most common birth defect and number one cause of infant mortality in the developed world. Twice as many children die from CHD than all childhood cancers combined. Current tissue-based percutaneous valves are expensive, difficult to manufacture, too bulky to be used in young children, and rendered ineffective by the immune system. Since 2014, we have led the effort to improve children's lives with polymeric transcatheter valves (PTV) for children that have no biological tissue. These valves are easy to manufacture in pediatric and adult sizes, expandable to accommodate growth of children, and reduces a need for repeat open-heart surgeries. Our aim is to transform the care of children with congenital heart disease by developing an entirely new generation of valves.